AURA | Ticker Profile - Titan Protect

AURA

Aura Biosciences, Inc.

Healthcare · Biotechnology · NGM

$6.63

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$792M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.77

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-95.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$17.00

+156% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Aura Biosciences, Inc.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

https://www.aurabiosciences.com

Country: United States Employees: 113 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.294

Positive but modest risk-adjusted returns

Kelly Fraction

0.0076

Marginal edge — very small allocation suggested

Calmar Ratio

-0.001

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-0.1%

Historical annualised return based on price data

Max Drawdown

-58.3%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.37

Very low correlation to market moves

52W High

$9.54

30% below the year high

52W Low

$4.73

40% above the year low

Avg Volume

478,911

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

3.7%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.71

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

15.84

Heavy leverage — higher financial risk if revenues decline

Current Ratio

7.09

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.87

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-51,558,752

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-112,393,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$24.00

Target Median

$17.00

Target Low

$15.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
9 Apr2026	Josh Gottheimer	Democrat	sell	15K–50K
6 Apr2026	Josh Gottheimer	Democrat	buy	1K–15K
2026-04-09	Josh Gottheimer	Democrat	Sale	15K–50K
2026-04-06	Josh Gottheimer	Democrat	Purchase	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go